World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 1, Number 3, June 2010, pages 118-128

Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients

**Table 1.** Clinicopathological data (n = 57)
	N	%
ER: Estrogen receptor; PR: Progesterone receptor; CPR: complete pathologic response; micro only: microscopic residual disease only.
Age
≤ 55 years	31	54.4
> 55 years	26	45.6
FIGO Stage
I/II	20	35.1
III/IV	37	64.9
Ascites
<100 ml	23	65.2
>100 ml	34	79.2
Cytology
Negative	28	71.4
Positive	29	75.9
Residual disease
None/Optimal	31	54.4
Suboptimal	26	45.6
Histologic type
Serous	24	42.1
Non serous	33	57.9
Tumor grade
I/II	34	59.6
III	23	40.4
p53
Negative	15	26.3
Positive	42	73.7
Bcl-2
Negative	30	52.6
Positive	27	47.4
ER
Negative	37	64.9
Positive	20	35.1
PR
Negative	38	66.7
Positive	19	33.3
Surgery
Optimal	31	54.4
Suboptimal	26	45.6
Systemic chemotherapy
Adjuvant	45	96.49
Neoadjuvant	2	3.51
Response
CPR and micro only	28	49.1
Partial	2	3.5
Stable and progression	15	26.3
Not assessable	12	21.0

Table 1. Clinicopathological data (n = 57)

ER: Estrogen receptor; PR: Progesterone receptor; CPR: complete pathologic response; micro only: microscopic residual disease only.

Age

≤ 55 years

54.4

> 55 years

45.6

FIGO Stage

I/II

35.1

III/IV

64.9

Ascites

<100 ml

65.2

>100 ml

79.2

Cytology

Negative

71.4

Positive

75.9

Residual disease

None/Optimal

54.4

Suboptimal

45.6

Histologic type

Serous

42.1

Non serous

57.9

Tumor grade

I/II

59.6

III

40.4

p53

Negative

26.3

Positive

73.7

Bcl-2

Negative

52.6

Positive

47.4

Negative

64.9

Positive

35.1

Negative

66.7

Positive

33.3

Surgery

Optimal

54.4

Suboptimal

45.6

Systemic chemotherapy

Adjuvant

96.49

Neoadjuvant

3.51

Response

CPR and micro only

49.1

Partial

3.5

Stable and progression

26.3

Not assessable

21.0

**Table 2.** Histologic Subtypes
Histologic subtypes	Number	%
Serous carcinoma	24	42.1
Endometrioid carcinoma	23	40.3
Malignant mixed epithelial tumour	4	7
Mucinous carcinoma	3	5.3
Undifferenciated carcinoma	2	3.5
Transitional cell carcinoma	1	1.8

Table 2. Histologic Subtypes

Histologic subtypes

Number

Serous carcinoma

42.1

Endometrioid carcinoma

40.3

Malignant mixed epithelial tumour

Mucinous carcinoma

5.3

Undifferenciated carcinoma

3.5

Transitional cell carcinoma

1.8

**Table 3.** Correlation Between ER and PR Expression (p = 0.000)
	ER	Total
ER: Estrogen receptor; PR: Progesterone receptor.
PR
Negative	33 (86.8%)	5 (13.2%)	38
Positive	4 (21.1%)	15 (78.9%)	19
Total	37	20	57

Table 3. Correlation Between ER and PR Expression (p = 0.000)

Total

Negative

Positive

ER: Estrogen receptor; PR: Progesterone receptor.

Negative

33 (86.8%)

5 (13.2%)

Positive

4 (21.1%)

15 (78.9%)

Total

**Table 4.** Correlation Between p53 and Bcl-2 Expression (p = 0.949)
	p53	Total
Bcl-2
Negative	8 (26.7%)	22 (73.3%)	30
Positive	7 (25.9%)	20 (74.1%)	27
Total	15	42	57

Table 4. Correlation Between p53 and Bcl-2 Expression (p = 0.949)

p53

Total

Negative

Positive

Bcl-2

Negative

8 (26.7%)

22 (73.3%)

Positive

7 (25.9%)

20 (74.1%)

Total

**Table 5.** Correlation Between P53 and Bcl-2 Expression With Clinico-pathological Data
	N	P53 Expression	Bcl-2 Expression
p¹: Chi-Square test; p²: Student test; %: Positivity percentage; SD: standard deviation.
Age (years)			0.611		0.372		0.153		0.230
≤ 55	31	71		3.23 ± 3.48		38.7		0. 84 ± 1.65
>55	26	76.9		4.08 ± 3.64		57.7		1.42 ± 1.98
FIGO Stage			0.085		0.026		0.169		0.893
I-II	20	60		2.20 ± 3.25		35		1.15 ± 2.27
III-IV	37	81.5		4.38 ± 3.50		54.1		1.08 ± 1.55
Residual disease			0.611		0.135		0.716		0.970
None/Optimal	31	71		2.97 ± 3.33		45.2		1.1 ± 1.98
Sub-optimal	26	76.9		4.38 ± 3.71		50		1.12 ± 1.63
Histologic type			0.847		0.320		0.462		0.271
Serous	24	75		4.17 ± 3.66		41.7		0.79 ± 1.35
No Serous	33	72.7		3.21 ± 3.46		51.5		1.33 ± 2.08
Histologic Grade			0.061		0.063		0.629		0.636
I-II	34	64.7		1.65 ± 0.48		50		1.50 ± 0.50
III	23	87		1.87 ± 0.34		43.5		1.43 ± 0.50
Ascites
<100 ml	23	65.2	0.230	3.35 ± 3.74	0.646	39.1	0.306	0.83 ± 1.58	0.345
>100 ml	34	79.2		3.79 ± 3.45		52.9		1.29 ± 1.96
Cytology					0.452		0.503		0.892
negative	28	71.4	0.700	3.25 ± 3.58		42.9		1.07 ± 1.96
positive	29	75.9		3.97 ± 3.54		51.7		1.14 ± 1.70

Table 5. Correlation Between P53 and Bcl-2 Expression With Clinico-pathological Data

P53 Expression

Bcl-2 Expression

p¹

Score ± SD

p²

p¹

Score ± SD

p²

p¹: Chi-Square test; p²: Student test; %: Positivity percentage; SD: standard deviation.

Age (years)

0.611

0.372

0.153

0.230

≤ 55

3.23 ± 3.48

38.7

0. 84 ± 1.65

>55

76.9

4.08 ± 3.64

57.7

1.42 ± 1.98

FIGO Stage

0.085

0.026

0.169

0.893

I-II

2.20 ± 3.25

1.15 ± 2.27

III-IV

81.5

4.38 ± 3.50

54.1

1.08 ± 1.55

Residual disease

0.611

0.135

0.716

0.970

None/Optimal

2.97 ± 3.33

45.2

1.1 ± 1.98

Sub-optimal

76.9

4.38 ± 3.71

1.12 ± 1.63

Histologic type

0.847

0.320

0.462

0.271

Serous

4.17 ± 3.66

41.7

0.79 ± 1.35

No Serous

72.7

3.21 ± 3.46

51.5

1.33 ± 2.08

Histologic Grade

0.061

0.063

0.629

0.636

I-II

64.7

1.65 ± 0.48

1.50 ± 0.50

III

1.87 ± 0.34

43.5

1.43 ± 0.50

Ascites

<100 ml

65.2

0.230

3.35 ± 3.74

0.646

39.1

0.306

0.83 ± 1.58

0.345

>100 ml

79.2

3.79 ± 3.45

52.9

1.29 ± 1.96

Cytology

0.452

0.503

0.892

negative

71.4

0.700

3.25 ± 3.58

42.9

1.07 ± 1.96

positive

75.9

3.97 ± 3.54

51.7

1.14 ± 1.70

**Table 6.** Correlation Between ER and PR Status With Clinico-pathological Data
	N	ER Expression	PR Expression
p¹: Chi-Square test; p²: Student test; %: positivity percentage; ER: Estrogen receptor; PR: Progesterone receptor; SD: standard deviation.
Age (years)			0.296		0.614		0.707		0.537
≤ 55	31	29		1.06 ± 2.30		35.5		1.87 ± 3.05
>55	26	42.3		1.38 ± 2.45		30.8		1.38 ± 2.80
FIGO Stage			0.568		0.105		0.170		0.045
I-II	20	40		1.90 ± 3.38		45		2.70 ± 3.68
III-IV	37	32.4		0.84 ± 1.48		27		1.08 ± 2.27
Residual disease			0.945		0.289		0.039		0.013
None/Optimal	31	35.5		1.52 ± 2.89		45.2		2.52 ± 3.45
Sub-optimal	26	34.6		0.85 ± 1.46		19.2		0.62 ± 1.67
Histologic type			0.813		0.570		0.088		0.010
Serous	24	33.3		1.00 ± 1.64		20.8		0.50 ± 1.06
No Serous	33	36.4		1.36 ± 2.78		42.4		2.48 ± 3.52
Histologic Grade			0.021		0.021		0.036		0.036
I-II	34	47.1		1.47 ± 0.50		44.1		1.44 ± 0.50
III	23	17.4		1.17 ± 0.38		17.4		1.17 ± 0.38
Ascites			0.599		0.986		0.84		0.933
<100 ml	23	39.1		1.22 ± 1.70		34.8		1.61 ± 2.72
>100 ml	34	32.4		1.21 ± 2.73		32.4		1.68 ± 3.09
Cytology			0.70		0.90		0.134		0.182
Negative	28	71.4		1.75 ± 3.02		42.9		2.18 ± 3.19
Positive	29	75.9		0.69 ± 1.31		24.1		1.14 ± 2.58

Table 6. Correlation Between ER and PR Status With Clinico-pathological Data

ER Expression

PR Expression

p¹

Score ± SD

p²

p¹

Score ± SD

p²

p¹: Chi-Square test; p²: Student test; %: positivity percentage; ER: Estrogen receptor; PR: Progesterone receptor; SD: standard deviation.

Age (years)

0.296

0.614

0.707

0.537

≤ 55

1.06 ± 2.30

35.5

1.87 ± 3.05

>55

42.3

1.38 ± 2.45

30.8

1.38 ± 2.80

FIGO Stage

0.568

0.105

0.170

0.045

I-II

1.90 ± 3.38

2.70 ± 3.68

III-IV

32.4

0.84 ± 1.48

1.08 ± 2.27

Residual disease

0.945

0.289

0.039

0.013

None/Optimal

35.5

1.52 ± 2.89

45.2

2.52 ± 3.45

Sub-optimal

34.6

0.85 ± 1.46

19.2

0.62 ± 1.67

Histologic type

0.813

0.570

0.088

0.010

Serous

33.3

1.00 ± 1.64

20.8

0.50 ± 1.06

No Serous

36.4

1.36 ± 2.78

42.4

2.48 ± 3.52

Histologic Grade

0.021

0.036

I-II

47.1

1.47 ± 0.50

44.1

1.44 ± 0.50

III

17.4

1.17 ± 0.38

17.4

1.17 ± 0.38

Ascites

0.599

0.986

0.84

0.933

<100 ml

39.1

1.22 ± 1.70

34.8

1.61 ± 2.72

>100 ml

32.4

1.21 ± 2.73

32.4

1.68 ± 3.09

Cytology

0.70

0.90

0.134

0.182

Negative

71.4

1.75 ± 3.02

42.9

2.18 ± 3.19

Positive

75.9

0.69 ± 1.31

24.1

1.14 ± 2.58